Cargando…
Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for th...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901401/ https://www.ncbi.nlm.nih.gov/pubmed/28575536 http://dx.doi.org/10.1002/acr.23299 |
_version_ | 1783314608494215168 |
---|---|
author | Webers, Casper Essers, Ivette van Tubergen, Astrid Braun, Jürgen Heldmann, Frank Baraliakos, Xenofon Boonen, Annelies |
author_facet | Webers, Casper Essers, Ivette van Tubergen, Astrid Braun, Jürgen Heldmann, Frank Baraliakos, Xenofon Boonen, Annelies |
author_sort | Webers, Casper |
collection | PubMed |
description | OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) were used. WTP was included at baseline in EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with WTP were explored using zero‐inflated negative binomial (ZINB) regressions. RESULTS: Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was €275 (median €100 [interquartile range €50–200]). Multivariable ZINB analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response was associated with a 7‐fold lower likelihood to pay 0 euros (odds ratio [OR] 0.14 [95% confidence interval (95% CI) 0.03–0.71]) and a 3‐fold increase in the amount willing to pay (exp(β) = 3.32 [95% CI 1.44–7.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (OR 0.07 [95% CI 0.02–0.36]), while increased age was associated with the amount willing to pay (exp(β) = 1.05 [95% CI 1.01–1.09]). CONCLUSION: In a hypothetical scenario, three‐quarters of patients with AS receiving long‐term infliximab stated that they were willing to pay an out‐of‐pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay. |
format | Online Article Text |
id | pubmed-5901401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-59014012018-04-24 Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach Webers, Casper Essers, Ivette van Tubergen, Astrid Braun, Jürgen Heldmann, Frank Baraliakos, Xenofon Boonen, Annelies Arthritis Care Res (Hoboken) Ankylosing Spondylitis OBJECTIVE: To investigate willingness to pay (WTP) for treatment with infliximab by patients with ankylosing spondylitis (AS) and explore factors associated with WTP. METHODS: Data from 85 patients participating in the European AS Infliximab Cohort (EASIC) open‐label extension of the AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) were used. WTP was included at baseline in EASIC and comprised a hypothetical scenario exploring whether the patient would be willing to pay for beneficial effects of infliximab and, if so, what amount they would be willing to pay per administration. Factors associated with WTP were explored using zero‐inflated negative binomial (ZINB) regressions. RESULTS: Of the 85 patients, 63 (74.1%) were willing to pay, and among these, the mean amount they were willing to pay per administration was €275 (median €100 [interquartile range €50–200]). Multivariable ZINB analysis showed that Assessment of SpondyloArthritis international Society criteria for 20% improvement (ASAS20) response was associated with a 7‐fold lower likelihood to pay 0 euros (odds ratio [OR] 0.14 [95% confidence interval (95% CI) 0.03–0.71]) and a 3‐fold increase in the amount willing to pay (exp(β) = 3.32 [95% CI 1.44–7.69]). In addition, the country of residence was associated with a lower likelihood to pay 0 euros (OR 0.07 [95% CI 0.02–0.36]), while increased age was associated with the amount willing to pay (exp(β) = 1.05 [95% CI 1.01–1.09]). CONCLUSION: In a hypothetical scenario, three‐quarters of patients with AS receiving long‐term infliximab stated that they were willing to pay an out‐of‐pocket contribution for this treatment. Treatment response contributed to the willingness as well as to the amount patients were willing to pay. John Wiley and Sons Inc. 2018-02-18 2018-04 /pmc/articles/PMC5901401/ /pubmed/28575536 http://dx.doi.org/10.1002/acr.23299 Text en © 2017, The Authors. Arthritis Care & Research published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Ankylosing Spondylitis Webers, Casper Essers, Ivette van Tubergen, Astrid Braun, Jürgen Heldmann, Frank Baraliakos, Xenofon Boonen, Annelies Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title | Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title_full | Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title_fullStr | Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title_full_unstemmed | Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title_short | Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach |
title_sort | valuing treatment with infliximab for ankylosing spondylitis using a willingness‐to‐pay approach |
topic | Ankylosing Spondylitis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901401/ https://www.ncbi.nlm.nih.gov/pubmed/28575536 http://dx.doi.org/10.1002/acr.23299 |
work_keys_str_mv | AT weberscasper valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT essersivette valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT vantubergenastrid valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT braunjurgen valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT heldmannfrank valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT baraliakosxenofon valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach AT boonenannelies valuingtreatmentwithinfliximabforankylosingspondylitisusingawillingnesstopayapproach |